Fibreoptic phototherapy for neonatal jaundice

J F Mills, D Tudehope, J F Mills, D Tudehope

Abstract

Background: Phototherapy is used to treat newborn infants with hyperbilirubinaemia. Fibreoptic phototherapy is a new mode of phototherapy which is reported to lower serum bilirubin (SBR) while minimising disruption of normal infant care.

Objectives: To evaluate the efficacy of fibreoptic phototherapy.

Search strategy: The standard search strategy of the Cochrane Collaboration was used including searches of the Cochrane Controlled Trials Register, MEDLINE, EMBASE and discussion with experts in the field.

Selection criteria: Randomised or quasi-randomised controlled trials evaluating the efficacy of fibreoptic phototherapy in the management of newborn infants with hyperbilirubinaemia.

Data collection and analysis: Thirty-one studies were identified of which 24 met inclusion criteria. They evaluated the efficacy of fibreoptic phototherapy in a number of different clinical situations and patient populations.

Main results: Fibreoptic phototherapy was more effective at lowering SBR than no treatment but less effective than conventional phototherapy (percentage change in SBR after 24 hours of treatment: WMD -10.7%, 95%CI -18.14, -3.26 and WMD 3.59%, 95%CI 1.27, 5.92 respectively). Fibreoptic phototherapy was equally as effective as conventional phototherapy in preterm infants and when two fibreoptic devices were used simultaneously (change in SBR after 24 hours of treatment: WMD 1.7%, 95%CI -2.65, 6.05 and change in SBR per day over whole treatment period: WMD 2.82%, 95%CI -1.84, 7.48 respectively). A combination of fibreoptic and conventional phototherapy was more effective than conventional phototherapy alone (duration of phototherapy: WMD -12.51 hr, 95%CI -16.00, -9.02, meta-analysis affected by heterogeneity). No conclusion can be made on the superiority of one fibreoptic device over another as the two studies comparing them (one favouring BiliBlanket, the other finding no difference) did not contain a common outcome measure.

Reviewer's conclusions: Fibreoptic phototherapy has a place in the management of neonatal hyperbilirubinaemia. It is probably a safe alternative to conventional phototherapy in term infants with physiological jaundice. No trials have been identified which support the widely-held view that fibreoptic devices interfere less with infant care or impact less on parent-child bonding.

Conflict of interest statement

None

Figures

1.1. Analysis
1.1. Analysis
Comparison 1 Fibreoptic phototherapy vs no treatment, Outcome 1 Use of exchange transfusion.
1.2. Analysis
1.2. Analysis
Comparison 1 Fibreoptic phototherapy vs no treatment, Outcome 2 Use of additional phototherapy.
1.3. Analysis
1.3. Analysis
Comparison 1 Fibreoptic phototherapy vs no treatment, Outcome 3 Change in serum bilirubin concentration over total treatment period (% change/hr).
1.4. Analysis
1.4. Analysis
Comparison 1 Fibreoptic phototherapy vs no treatment, Outcome 4 Change in serum bilirubin concentration over total treatment period (%change/d).
2.1. Analysis
2.1. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 1 Duration of phototherapy (hr).
2.2. Analysis
2.2. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 2 Use of exchange transfusion.
2.3. Analysis
2.3. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 3 Use of additional phototherapy.
2.4. Analysis
2.4. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/d).
2.5. Analysis
2.5. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 5 Change in serum bilirubin concentration over total treatment period (% change/hr).
2.6. Analysis
2.6. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 6 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
2.7. Analysis
2.7. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 7 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
2.8. Analysis
2.8. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 8 Use of repeat phototherapy for rebound jaundice.
2.9. Analysis
2.9. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 9 Maternal migraine.
2.10. Analysis
2.10. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 10 Trans‐epidermal water loss (mL/m2/hr).
2.11. Analysis
2.11. Analysis
Comparison 2 Fibreoptic vs conventional phototherapy, Outcome 11 Mesenteric blood flow velocity (m/s).
3.1. Analysis
3.1. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 1 Duration of phototherapy (hr).
3.2. Analysis
3.2. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 2 Use of additional phototherapy.
3.3. Analysis
3.3. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 3 Change in serum bilirubin concentration over total treatment period (% change/d).
3.4. Analysis
3.4. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/hr).
3.5. Analysis
3.5. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 5 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
3.6. Analysis
3.6. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 6 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
3.7. Analysis
3.7. Analysis
Comparison 3 Fibreoptic vs conventional phototherapy with white light, Outcome 7 Use of repeat phototherapy for rebound jaundice.
4.1. Analysis
4.1. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 1 Duration of phototherapy (hr).
4.2. Analysis
4.2. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 2 Use of exchange transfusion.
4.3. Analysis
4.3. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 3 Use of additional phototherapy.
4.4. Analysis
4.4. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/d).
4.5. Analysis
4.5. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 5 Change in serum bilirubin concentration over total treatment period (% change/hr).
4.6. Analysis
4.6. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 6 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
4.7. Analysis
4.7. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 7 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
4.8. Analysis
4.8. Analysis
Comparison 4 Fibreoptic vs conventional phototherapy with blue light, Outcome 8 Use of repeat phototherapy for rebound jaundice.
5.1. Analysis
5.1. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 1 Duration of phototherapy (hr).
5.2. Analysis
5.2. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 2 Use of exchange transfusion.
5.3. Analysis
5.3. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 3 Use of additional phototherapy.
5.4. Analysis
5.4. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/d).
5.5. Analysis
5.5. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 5 Change in serum bilirubin concentration over total treatment period (% change/hr).
5.6. Analysis
5.6. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 6 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
5.7. Analysis
5.7. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 7 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
5.8. Analysis
5.8. Analysis
Comparison 5 Fibreoptic vs conventional phototherapy with a combination of white and blue light, Outcome 8 Use of repeat phototherapy for rebound jaundice.
6.1. Analysis
6.1. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 1 Duration of phototherapy (hr).
6.2. Analysis
6.2. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 2 Use of exchange transfusion.
6.3. Analysis
6.3. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 3 Use of additional phototherapy.
6.4. Analysis
6.4. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/d).
6.5. Analysis
6.5. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 5 Change in serum bilirubin concentration over total treatment period (% change/hr).
6.6. Analysis
6.6. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 6 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
6.7. Analysis
6.7. Analysis
Comparison 6 Fibreoptic vs conventional phototherapy in preterm infants, Outcome 7 Use of repeat phototherapy for rebound jaundice.
7.1. Analysis
7.1. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 1 Duration of phototherapy (hr).
7.2. Analysis
7.2. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 2 Use of exchange transfusion.
7.3. Analysis
7.3. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 3 Use of additional phototherapy.
7.4. Analysis
7.4. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/d).
7.5. Analysis
7.5. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 5 Change in serum bilirubin concentration over total treatment period (% change/hr).
7.6. Analysis
7.6. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 6 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
7.7. Analysis
7.7. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 7 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
7.8. Analysis
7.8. Analysis
Comparison 7 BiliBlanket vs conventional phototherapy, Outcome 8 Use of repeat phototherapy for rebound jaundice.
8.1. Analysis
8.1. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 1 Duration of phototherapy (hr).
8.2. Analysis
8.2. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 2 Use of additional phototherapy.
8.3. Analysis
8.3. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 3 Change in serum bilirubin concentration over total treatment period (% change/d).
8.4. Analysis
8.4. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/hr).
8.5. Analysis
8.5. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 5 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
8.6. Analysis
8.6. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 6 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
8.7. Analysis
8.7. Analysis
Comparison 8 Wallaby vs conventional phototherapy, Outcome 7 Use of repeat phototherapy for rebound jaundice.
9.1. Analysis
9.1. Analysis
Comparison 9 Double fibreoptic phototherapy vs conventional phototherapy, Outcome 1 Duration of phototherapy (hr).
9.2. Analysis
9.2. Analysis
Comparison 9 Double fibreoptic phototherapy vs conventional phototherapy, Outcome 2 Use of additional phototherapy.
9.3. Analysis
9.3. Analysis
Comparison 9 Double fibreoptic phototherapy vs conventional phototherapy, Outcome 3 Change in serum bilirubin concentration over total treatment period (% change/d).
9.4. Analysis
9.4. Analysis
Comparison 9 Double fibreoptic phototherapy vs conventional phototherapy, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/hr).
9.5. Analysis
9.5. Analysis
Comparison 9 Double fibreoptic phototherapy vs conventional phototherapy, Outcome 5 Use of repeat phototherapy for rebound jaundice.
10.1. Analysis
10.1. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 1 Duration of phototherapy (hr).
10.2. Analysis
10.2. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 2 Use of exchange transfusion.
10.3. Analysis
10.3. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 3 Use of additional phototherapy.
10.4. Analysis
10.4. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 4 Change in serum bilirubin concentration over total treatment period (% change/d).
10.5. Analysis
10.5. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 5 Change in serum bilirubin concentration over total treatment period (% change/hr).
10.6. Analysis
10.6. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 6 Change in serum bilirubin concentration over first 24 hours of treatment (% change/24 hr).
10.7. Analysis
10.7. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 7 Change in serum bilirubin concentration over first 48 hours of treatment (% change/48 hr).
10.8. Analysis
10.8. Analysis
Comparison 10 Combination phototherapy (fibreoptic and conventional) vs conventional phototherapy, Outcome 8 Use of repeat phototherapy for rebound jaundice.
11.1. Analysis
11.1. Analysis
Comparison 11 BiliBlanket vs Wallaby phototherapy system, Outcome 1 Use of additional phototherapy.
11.2. Analysis
11.2. Analysis
Comparison 11 BiliBlanket vs Wallaby phototherapy system, Outcome 2 Change in serum bilirubin concentration over total treatment period (% change/hr).
11.3. Analysis
11.3. Analysis
Comparison 11 BiliBlanket vs Wallaby phototherapy system, Outcome 3 Use of repeat phototherapy for rebound jaundice.

Source: PubMed

3
Subscribe